RBMX and glioblastoma: Subsequently, we verified the presence of aberrant RBMX protein levels in clinical liver hepatocellular carcinoma (LIHC), glioblastoma (GBM), and cholangiocarcinoma (CHOL) samples compared with adjacent tissues.